G1 Therapeutics (GTHX) Downgraded by BidaskClub to Hold

G1 Therapeutics (NASDAQ:GTHX) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Several other research analysts have also recently weighed in on GTHX. Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 8th. HC Wainwright reissued a “buy” rating and issued a $79.00 target price on shares of G1 Therapeutics in a research note on Monday, September 17th. ValuEngine raised G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Needham & Company LLC increased their target price on G1 Therapeutics to $76.00 and gave the company a “buy” rating in a research note on Tuesday, September 18th. Finally, BTIG Research began coverage on G1 Therapeutics in a research note on Monday, September 10th. They issued a “buy” rating and a $80.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $74.50.

G1 Therapeutics stock opened at $56.47 on Thursday. The firm has a market capitalization of $1.92 billion, a PE ratio of -15.82 and a beta of -1.32. G1 Therapeutics has a fifty-two week low of $18.03 and a fifty-two week high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.01. research analysts expect that G1 Therapeutics will post -2.68 EPS for the current year.

In related news, SVP Terry L. Murdock sold 3,519 shares of the stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $59.98, for a total value of $211,069.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajesh Malik sold 3,776 shares of the stock in a transaction on Monday, September 17th. The shares were sold at an average price of $66.08, for a total value of $249,518.08. The disclosure for this sale can be found here. In the last three months, insiders sold 53,064 shares of company stock worth $2,947,787. 15.92% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC increased its stake in G1 Therapeutics by 484.5% in the first quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock valued at $104,000 after acquiring an additional 2,316 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in G1 Therapeutics by 58.4% during the first quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after buying an additional 1,045 shares during the period. Great West Life Assurance Co. Can boosted its position in G1 Therapeutics by 148.3% during the second quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after buying an additional 1,560 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its position in G1 Therapeutics by 44.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after buying an additional 1,200 shares during the period. Finally, Strs Ohio boosted its position in G1 Therapeutics by 78.3% during the second quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after buying an additional 1,800 shares during the period. 69.17% of the stock is currently owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Read More: Exchange-Traded Funds (ETFs)

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply